Biocytogen

Your Partner From Targets To Therapeutics

[Biocytogen @biocytogen]

Biocytogen has been awarded a U.S. patent for our RenLite® fully human common light chain mouse platform! We've created a robust library of antibodies targeting over 200 TAA targets, accelerating bispecific antibody and ADC therapies.

#Biotech #AntibodyDevelopment

[Biocytogen @biocytogen]

From Target to Therapeutics with Humanized Mouse Models by Yuan Tian https://t.co/99vjHtRfEO

[Biocytogen @biocytogen]

🌞 Join Biocytogen for a Biotech Happy Hour at the Lighthouse Cafe in South San Francisco on June 12, 2024 from 3 p.m. to 7 p.m. Enjoy a complimentary drink, network with industry colleagues! Register here: https://t.co/YSWIL4etx9
#Biotech #Networking #HappyHour

[Biocytogen @biocytogen]

🧀🐭 Happy National Cheese Day from Biocytogen! 🐭🧀 Let's celebrate with a virtual slice of cheese for our mighty mice heroes! 🧀🐭

#NationalCheeseDay #Biocytogen #HumanizedMice #ScienceWithCheese #SayCheese #Biotech

[Biocytogen @biocytogen]

Additionally, CD47 signaling stimulates the formation of new blood vessels, supporting tumor growth and metastasis. Check out our B-hCD47 mice: https://t.co/4F8AnxbcEY

#immunecheckpoint #invivo #therapeutics #immunotherapy #antitumortherapy #cancertherapy #cancerresearch

[Biocytogen @biocytogen]

CD47 is instrumental in cancer progression by aiding immune evasion, promoting angiogenesis & facilitating tumor cell survival & metastasis. Through its interaction with macrophage receptors, CD47 prevents the phagocytosis of cancer cells, enabling them to evade immune detection.

[Biocytogen @biocytogen]

CD47 is instrumental in cancer progression by aiding immune evasion, promoting angiogenesis & facilitating tumor cell survival & metastasis. Through its interaction with macrophage receptors, CD47 prevents the phagocytosis of cancer cells, enabling them to evade immune detection.

[Biocytogen @biocytogen]

✔️ Monoclonal antibodies (mAbs) against Nectin-4, FGFR2b, CEACAM6, and ROR1 exhibit high target affinity & species cross-reactivity.

Catch our poster C017 at #PEGSBoston 2024 on May 16th or reach out for data &partnership opportunities: [email protected]
#BreastCancer

[Biocytogen @biocytogen]

🎗️With 2.3M new cases & 670K deaths yearly, breast cancer necessitates innovative solutions. Triple-negative breast Cancer (TNBC) presents formidable challenges, but our novel assets offer hope:
✔️Bispecific ADCs like BCG023 & BCG033 show promising efficacy in preclinical studies

[Biocytogen @biocytogen]

🎗️With 2.3M new cases & 670K deaths yearly, breast cancer necessitates innovative solutions. Triple-negative breast Cancer (TNBC) presents formidable challenges, but our novel assets offer hope:
✔️Bispecific ADCs like BCG023 & BCG033 show promising efficacy in preclinical studies

[Biocytogen @biocytogen]

Day 2 at #PEGSboston! Swing by booth #23 for a chat and learn about our BioMice and Renbiologics assets, ranging from preclinical animal models and pharmacology evaluation services to antibody assets for licensing. https://t.co/fqguoZ9gXm

#PEGSBoston #PEGS2024 #AntibodyLibrary

[Biocytogen @biocytogen]

Our anti-PD-L1 mAb demonstrates robust blocking activity &in vivo efficacy, while our anti-TNFR2 mAb exhibits potent ADCC effect &agonist activity. Our TAA-targeting mAbs &novel bsADCs display high target affinity. Download our poster for more👉https://t.co/v2j5KsnzjN

[Biocytogen @biocytogen]

Lung cancer, a primary contributor to cancer-related deaths, impacts millions globally. @biocytogen is pioneering the advancement of novel therapeutic options for non-small cell lung cancer (NSCLC) through the discovery of fully human monoclonal antibodies (mAbs) &bispecific ADCs

[Biocytogen @biocytogen]

Lung cancer, a primary contributor to cancer-related deaths, impacts millions globally. @biocytogen is pioneering the advancement of novel therapeutic options for non-small cell lung cancer (NSCLC) through the discovery of fully human monoclonal antibodies (mAbs) &bispecific ADCs

[Biocytogen @biocytogen]

We have pioneered the development of monoclonal antibodies (mAbs) & TCR-mimic antibodies for TCRm-T cell therapy aimed at treating sarcomas. Download NY-ESO-1/HLA-A02 poster to learn more: https://t.co/B9omo6K33b #SarcomaResearch #Immunotherapy #antibodylibrary #renbiologics

[Biocytogen @biocytogen]

Sarcomas, the 2nd most common type of solid tumor affecting children&adolescents, encompasses about 100 distinct subtypes, originating from diverse tissues such as bone &muscle. Conventional treatment approaches often fall short, particularly in cases diagnosed at advanced stages

[Biocytogen @biocytogen]

Sarcomas, the 2nd most common type of solid tumor affecting children&adolescents, encompasses about 100 distinct subtypes, originating from diverse tissues such as bone &muscle. Conventional treatment approaches often fall short, particularly in cases diagnosed at advanced stages

[Biocytogen @biocytogen]

🌟 May 2024 Newsletter 🌟

Check out our New Mouse Models, Cell Lines, New Promotion and Upcoming events! https://t.co/KXEYMDUemh

#LatestUpdates #DontMissOut #newsletter #may2024 #mousemodel #humanizedmodel #innovation #immunotherapy #cancerresearch #cancertherapy

[Biocytogen @biocytogen]

Our Poster number is C017. You don't want to miss it! See you there! https://t.co/fqguoZ9gXm

#PEGSBoston #PEGS2024 #AntibodyTherapeutics #AntibodyLibrary #Biologics #preclinical #renbiologics #antibody #cancer #biotech #nanobody #adc #renmice

[Biocytogen @biocytogen]

Attending PEGS Boston 2024 next week?

Swing by Booth #23 & check out our poster on Thur, May 16th! We'll be presenting "Generation of a Fully Human Antibody Library &Novel Linker/Payload to Facilitate Development of Antibody-Drug Conjugates &Other Antibody-Based Therapeutics”!

[Biocytogen @biocytogen]

Attending PEGS Boston 2024 next week?

Swing by Booth #23 & check out our poster on Thur, May 16th! We'll be presenting "Generation of a Fully Human Antibody Library &Novel Linker/Payload to Facilitate Development of Antibody-Drug Conjugates &Other Antibody-Based Therapeutics”!

[Biocytogen @biocytogen]

contributing to inflammation. IL-17 misregulation is associated with psoriasis, autoimmune encephalitis, rheumatoid arthritis, asthma, lupus, and anti-tumor immunity. It is also essential for the function of T helper 17 cells. Check out our B-hIL17A Mice: https://t.co/jhYjMVRQg7

[Biocytogen @biocytogen]

The IL-17 cytokine family plays diverse roles in immune regulation, inducing proinflammatory responses & allergic reactions by stimulating various immune signaling molecules. It promotes the production of cytokines, chemokines & prostaglandins from different cell types

[Biocytogen @biocytogen]

The IL-17 cytokine family plays diverse roles in immune regulation, inducing proinflammatory responses & allergic reactions by stimulating various immune signaling molecules. It promotes the production of cytokines, chemokines & prostaglandins from different cell types

[Biocytogen @biocytogen]

Join us at booth #2388 at #ASGCT2024 by American Society of Gene & Cell Therapy in Baltimore, MD from May 7-11! Explore our 100% guaranteed service & learn how our humanized models, disease models& pharmacology services can enhance your Cell &Gene Therapy! https://t.co/zAUzHwhAew

[Biocytogen @biocytogen]

Exciting news! We entered into an evaluation and potential licensing agreement with BioCopy AG! BioCopy will test our TCR-mimic antibodies against promising intracellular TAAs for the development of next-generation oncological drugs: https://t.co/uhybMXnKIF #Collaboration